You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAldosterone
Accession NumberDB04630
TypeSmall Molecule
GroupsExperimental
DescriptionA hormone secreted by the adrenal cortex that regulates electrolyte and water balance by increasing the renal retention of sodium and the excretion of potassium. [PubChem]
Structure
Thumb
Synonyms
(+)-aldosterone
11beta,21-Dihydroxy-3,20-diketo-4-pregnen-18-al
11beta,21-Dihydroxy-3,20-diketopregn-4-ene-18-al
11beta,21-dihydroxy-3,20-dioxo-4-pregnen-18-al
11beta,21-dihydroxy-3,20-dioxo-pregn-4-ene-18-al
11beta,21-dihydroxy-3,20-dioxopregn-4-en-18-al
11beta,21-Dihydroxypregn-4-ene-3,18,20-trione
18-Aldocorticosterone
18-Formyl-11beta,21-dihydroxy-4-pregnene-3,20-dione
18-Oxocorticosterone
Aldocorten
Aldocortene
Aldocortin
Aldosterona
Aldosteronum
D-aldosterone
Electrocortin
Elektrocortin
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII4964P6T9RB
CAS number52-39-1
WeightAverage: 360.444
Monoisotopic: 360.193674006
Chemical FormulaC21H28O5
InChI KeyPQSUYGKTWSAVDQ-ZVIOFETBSA-N
InChI
InChI=1S/C21H28O5/c1-20-7-6-13(24)8-12(20)2-3-14-15-4-5-16(18(26)10-22)21(15,11-23)9-17(25)19(14)20/h8,11,14-17,19,22,25H,2-7,9-10H2,1H3/t14-,15-,16+,17-,19+,20-,21+/m0/s1
IUPAC Name
(1S,2R,10S,11S,14S,15R,17S)-17-hydroxy-14-(2-hydroxyacetyl)-2-methyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-ene-15-carbaldehyde
SMILES
[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])[C@@]([H])(O)C[C@]12C=O)C(=O)CO
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsAt the late distal tubule and collecting duct, aldosterone has two main actions: 1) aldosterone acts on mineralocorticoid receptors (MR) on principal cells in the distal tubule of the kidney nephron, increasing the permeability of their apical (luminal) membrane to potassium and sodium and activates their basolateral Na+/K+ pumps, stimulating ATP hydrolysis leading to phosphorylation of the pump and a conformational change in the pump exposes the Na+ ions to the outside. The phosphorylated form of the pump has a low affinity for Na+ ions, hence reabsorbing sodium (Na+) ions and water into the blood, and secreting potassium (K+) ions into the urine; 2) aldosterone stimulates H+ secretion by intercalated cells in the collecting duct, regulating plasma bicarbonate (HCO3−) levels and its acid/base balance; and 3) aldosterone may act on the central nervous system via the posterior pituitary gland to release vasopressin (ADH) which serves to conserve water by direct actions on renal tubular resorption.
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Mineralocorticoid receptorProteinunknownNot AvailableHumanP08235 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism
SubstrateEnzymesProduct
Aldosterone
Not Available
Aldosterone 18-glucuronideDetails
Aldosterone
Not Available
Tetrahydroaldosterone-3-glucuronideDetails
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Aldosterone is combined with 1,10-Phenanthroline.Experimental
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Aldosterone.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Aldosterone.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Aldosterone.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Aldosterone.Investigational
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Aldosterone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Aldosterone.Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Aldosterone.Approved
AlbendazoleThe serum concentration of Aldosterone can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinAldosterone may decrease the antineoplastic activities of Aldesleukin.Approved
AlectinibThe serum concentration of Aldosterone can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Aldosterone can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Aldosterone.Approved, Investigational
ALT-110The risk or severity of adverse effects can be increased when Aldosterone is combined with ALT-110.Investigational
Aluminum hydroxideThe bioavailability of Aldosterone can be decreased when combined with Aluminum hydroxide.Approved
Aluminum phosphateThe bioavailability of Aldosterone can be decreased when combined with Aluminum phosphate.Approved
AmantadineThe serum concentration of Aldosterone can be increased when it is combined with Amantadine.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Aldosterone is combined with Ambenonium.Approved
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Aldosterone.Approved, Investigational
Aminohippuric acidThe serum concentration of Aldosterone can be increased when it is combined with Aminohippuric acid.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Aldosterone.Approved
AmiodaroneThe serum concentration of Aldosterone can be decreased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Aldosterone.Approved
AmlodipineThe serum concentration of Aldosterone can be increased when it is combined with Amlodipine.Approved
Amphotericin BAldosterone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Aldosterone can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Aldosterone can be increased when it is combined with Amsacrine.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Aldosterone.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Aldosterone.Approved
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Aldosterone.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Aldosterone.Approved, Investigational
AprepitantThe serum concentration of Aldosterone can be increased when it is combined with Aprepitant.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Aldosterone.Approved, Investigational
AstemizoleThe serum concentration of Aldosterone can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Aldosterone.Approved, Investigational
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Aldosterone.Approved
AtorvastatinThe serum concentration of Aldosterone can be increased when it is combined with Atorvastatin.Approved
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Aldosterone.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Aldosterone.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Aldosterone.Withdrawn
AzelastineThe serum concentration of Aldosterone can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Aldosterone can be increased when it is combined with Azithromycin.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Aldosterone.Approved, Investigational
BazedoxifeneThe serum concentration of Aldosterone can be increased when it is combined with Bazedoxifene.Approved, Investigational
BendroflumethiazideAldosterone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Aldosterone.Withdrawn
BenzocaineThe serum concentration of Aldosterone can be increased when it is combined with Benzocaine.Approved
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Aldosterone.Approved
BepridilThe serum concentration of Aldosterone can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Aldosterone.Approved, Vet Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Aldosterone.Investigational
BiperidenThe serum concentration of Aldosterone can be increased when it is combined with Biperiden.Approved
Bismuth SubcitrateThe bioavailability of Aldosterone can be decreased when combined with Bismuth Subcitrate.Approved
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Aldosterone.Approved
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Aldosterone.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Aldosterone.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Aldosterone.Approved
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Aldosterone.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Aldosterone.Investigational
BumetanideAldosterone may increase the hypokalemic activities of Bumetanide.Approved
BuprenorphineThe serum concentration of Aldosterone can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Aldosterone can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Aldosterone.Approved
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Aldosterone.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Aldosterone.Approved, Nutraceutical
Calcium carbonateThe bioavailability of Aldosterone can be decreased when combined with Calcium carbonate.Approved
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Aldosterone.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Aldosterone.Approved
CandesartanThe serum concentration of Aldosterone can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Aldosterone can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Aldosterone can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Aldosterone.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Aldosterone.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of Aldosterone can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Aldosterone can be increased when it is combined with Caspofungin.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Aldosterone.Experimental
CDX-110The risk or severity of adverse effects can be increased when Aldosterone is combined with CDX-110.Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Aldosterone.Approved, Investigational
CeritinibAldosterone may increase the hyperglycemic activities of Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Aldosterone.Withdrawn
ChloroquineThe serum concentration of Aldosterone can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideAldosterone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Aldosterone can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Aldosterone.Approved, Vet Approved
ChlorpropamideThe serum concentration of Aldosterone can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Aldosterone can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneAldosterone may increase the hypokalemic activities of Chlorthalidone.Approved
CholesterolThe serum concentration of Aldosterone can be increased when it is combined with Cholesterol.Experimental
CholestyramineCholestyramine can cause a decrease in the absorption of Aldosterone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cholic AcidThe serum concentration of Aldosterone can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Aldosterone can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Aldosterone can be decreased when it is combined with Cimetidine.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Ciprofloxacin.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Aldosterone.Approved
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Aldosterone.Approved
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Aldosterone.Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Aldosterone.Approved, Illicit
ClofazimineThe serum concentration of Aldosterone can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Aldosterone.Approved, Investigational
ClomipramineThe serum concentration of Aldosterone can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Aldosterone.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Aldosterone.Approved
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Aldosterone.Approved, Nutraceutical
ClotrimazoleThe serum concentration of Aldosterone can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Aldosterone.Approved
CobicistatThe serum concentration of Aldosterone can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Aldosterone.Approved
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Aldosterone.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Aldosterone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Aldosterone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColforsinThe serum concentration of Aldosterone can be increased when it is combined with Colforsin.Experimental
Conjugated Equine EstrogensThe serum concentration of Aldosterone can be increased when it is combined with Conjugated Equine Estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Aldosterone.Approved
CoumaphosThe risk or severity of adverse effects can be increased when Aldosterone is combined with Coumaphos.Vet Approved
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Aldosterone.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Aldosterone.Investigational
CyclophosphamideThe serum concentration of Aldosterone can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Aldosterone can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Aldosterone.Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Aldosterone.Approved
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Aldosterone.Approved
DaclatasvirThe serum concentration of Aldosterone can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Aldosterone.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Aldosterone.Approved
DarunavirThe serum concentration of Aldosterone can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Aldosterone.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Aldosterone.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Aldosterone.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Aldosterone is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Aldosterone is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Aldosterone is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Aldosterone.Investigational
DesipramineThe serum concentration of Aldosterone can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Aldosterone can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Aldosterone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Aldosterone can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Aldosterone.Approved, Illicit, Vet Approved
DichlorvosThe risk or severity of adverse effects can be increased when Aldosterone is combined with Dichlorvos.Vet Approved
DiclofenacThe serum concentration of Aldosterone can be increased when it is combined with Diclofenac.Approved, Vet Approved
DienestrolThe serum concentration of Aldosterone can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Aldosterone can be increased when it is combined with Diethylstilbestrol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Aldosterone.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Aldosterone.Approved
DigoxinThe serum concentration of Aldosterone can be decreased when it is combined with Digoxin.Approved
DihydroergotamineThe serum concentration of Aldosterone can be increased when it is combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Aldosterone.Illicit
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Aldosterone.Approved
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Aldosterone.Approved
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Aldosterone.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Aldosterone.Approved, Investigational, Vet Approved
DonepezilThe risk or severity of adverse effects can be increased when Aldosterone is combined with Donepezil.Approved
DoxazosinThe serum concentration of Aldosterone can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Aldosterone can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Aldosterone.Approved, Investigational
DronabinolThe serum concentration of Aldosterone can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Aldosterone can be increased when it is combined with Dronedarone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Aldosterone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Aldosterone.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Aldosterone.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Aldosterone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Aldosterone is combined with Echothiophate.Approved
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Aldosterone.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Aldosterone is combined with Edrophonium.Approved
ElbasvirThe serum concentration of Aldosterone can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Aldosterone.Approved, Investigational
EnalaprilThe serum concentration of Aldosterone can be increased when it is combined with Enalapril.Approved, Vet Approved
EnoxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Aldosterone can be increased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Aldosterone.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Aldosterone.Approved
ErgonovineThe serum concentration of Aldosterone can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Aldosterone can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Aldosterone.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Aldosterone.Approved, Vet Approved
EstradiolThe serum concentration of Aldosterone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Aldosterone can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Aldosterone can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Aldosterone can be increased when it is combined with Estrone.Approved
Etacrynic acidAldosterone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Aldosterone.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Aldosterone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Aldosterone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Aldosterone.Approved
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Aldosterone.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Aldosterone.Approved, Investigational
EtravirineThe serum concentration of Aldosterone can be increased when it is combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Aldosterone.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Aldosterone.Investigational
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Aldosterone.Approved
FelodipineThe serum concentration of Aldosterone can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Aldosterone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Aldosterone.Approved
FentanylThe serum concentration of Aldosterone can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe risk or severity of adverse effects can be increased when Aldosterone is combined with Fenthion.Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Aldosterone.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Aldosterone.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Aldosterone.Approved
FleroxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Aldosterone.Approved, Withdrawn
FluconazoleThe serum concentration of Aldosterone can be increased when it is combined with Fluconazole.Approved
FlumequineThe risk or severity of adverse effects can be increased when Aldosterone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Aldosterone.Vet Approved
FluoxetineThe serum concentration of Aldosterone can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluoxymesteroneAldosterone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlupentixolThe serum concentration of Aldosterone can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Aldosterone can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Aldosterone can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Aldosterone.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Aldosterone.Approved
FluvoxamineThe serum concentration of Aldosterone can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosaprepitantThe serum concentration of Aldosterone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Aldosterone can be decreased when it is combined with Fosphenytoin.Approved
FurosemideAldosterone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Aldosterone is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Aldosterone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Aldosterone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Gatifloxacin.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Aldosterone.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Aldosterone.Approved
GemifloxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Aldosterone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Aldosterone is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Aldosterone is combined with Ginkgo biloba.Approved, Nutraceutical
GlyburideThe serum concentration of Aldosterone can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Aldosterone can be increased when it is combined with Glycerol.Experimental
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Aldosterone.Approved
Gramicidin DThe serum concentration of Aldosterone can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Aldosterone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Grepafloxacin.Withdrawn
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Aldosterone.Approved
HexestrolThe serum concentration of Aldosterone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Aldosterone.Investigational
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Aldosterone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Aldosterone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Aldosterone.Approved, Investigational
HydrochlorothiazideAldosterone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Aldosterone.Approved, Vet Approved
HydroflumethiazideAldosterone may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Aldosterone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Aldosterone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Aldosterone.Approved
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Aldosterone.Approved
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Aldosterone.Approved
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Aldosterone.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Aldosterone.Approved
IndapamideAldosterone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Aldosterone can be decreased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Aldosterone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Aldosterone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Aldosterone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Aldosterone is combined with INGN 225.Investigational
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Aldosterone.Approved, Investigational
IsavuconazoniumThe serum concentration of Aldosterone can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Aldosterone is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Aldosterone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Aldosterone.Withdrawn
ItraconazoleThe serum concentration of Aldosterone can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Aldosterone can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Aldosterone.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Aldosterone.Experimental
KetamineThe serum concentration of Aldosterone can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Aldosterone.Approved
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Aldosterone.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Aldosterone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Aldosterone.Approved
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Aldosterone.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Aldosterone.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Aldosterone.Approved, Investigational
LapatinibThe serum concentration of Aldosterone can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Aldosterone.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Aldosterone.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Aldosterone.Approved
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Aldosterone.Approved
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Aldosterone.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Levofloxacin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Aldosterone.Approved
LevothyroxineThe serum concentration of Aldosterone can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Aldosterone can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Aldosterone.Approved
LiothyronineThe serum concentration of Aldosterone can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Aldosterone can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Aldosterone can be increased when it is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Aldosterone.Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Lomefloxacin.Approved
LomitapideThe serum concentration of Aldosterone can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Aldosterone.Approved
LopinavirThe serum concentration of Aldosterone can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Aldosterone can be increased when it is combined with Loratadine.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Aldosterone.Approved
LosartanThe serum concentration of Losartan can be decreased when it is combined with Aldosterone.Approved
LovastatinThe serum concentration of Aldosterone can be increased when it is combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Aldosterone.Approved
LumacaftorThe serum concentration of Aldosterone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Aldosterone.Approved, Investigational
MagaldrateThe bioavailability of Aldosterone can be decreased when combined with Magaldrate.Withdrawn
Magnesium carbonateThe bioavailability of Aldosterone can be decreased when combined with Magnesium carbonate.Approved
Magnesium hydroxideThe bioavailability of Aldosterone can be decreased when combined with Magnesium hydroxide.Approved
Magnesium oxideThe bioavailability of Aldosterone can be decreased when combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Aldosterone.Approved
Magnesium TrisilicateThe bioavailability of Aldosterone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Aldosterone is combined with Malathion.Approved, Investigational
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Aldosterone.Approved, Investigational
MaprotilineThe serum concentration of Aldosterone can be increased when it is combined with Maprotiline.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Aldosterone.Approved
MebendazoleThe serum concentration of Aldosterone can be increased when it is combined with Mebendazole.Approved, Vet Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Aldosterone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Aldosterone.Approved
MefloquineThe serum concentration of Aldosterone can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Aldosterone can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Aldosterone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Aldosterone is combined with Memantine.Approved, Investigational
MeprobamateThe serum concentration of Aldosterone can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Aldosterone.Approved
MestranolThe serum concentration of Aldosterone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Aldosterone.Withdrawn
MethadoneThe serum concentration of Aldosterone can be increased when it is combined with Methadone.Approved
MethallenestrilThe serum concentration of Aldosterone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Aldosterone is combined with Methanesulfonyl Fluoride.Investigational
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Aldosterone.Approved
MethyclothiazideAldosterone may increase the hypokalemic activities of Methyclothiazide.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Aldosterone.Approved, Vet Approved
MethyltestosteroneAldosterone may increase the fluid retaining activities of Methyltestosterone.Approved
MetolazoneAldosterone may increase the hypokalemic activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Aldosterone.Approved, Investigational
MibefradilThe serum concentration of Aldosterone can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Aldosterone can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Aldosterone.Approved, Illicit
MifepristoneThe therapeutic efficacy of Aldosterone can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Aldosterone is combined with Minaprine.Approved
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Aldosterone.Approved
MitomycinThe serum concentration of Aldosterone can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Aldosterone can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Aldosterone.Approved, Investigational
MivacuriumMivacurium may increase the adverse neuromuscular activities of Aldosterone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Aldosterone.Investigational
MorphineThe serum concentration of Morphine can be decreased when it is combined with Aldosterone.Approved, Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Aldosterone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Aldosterone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Aldosterone.Approved
NadololThe serum concentration of Nadolol can be decreased when it is combined with Aldosterone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Aldosterone.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Aldosterone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Aldosterone is combined with Nalidixic Acid.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Aldosterone.Approved, Vet Approved
NaltrexoneThe serum concentration of Aldosterone can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Aldosterone.Approved, Vet Approved
NaringeninThe serum concentration of Aldosterone can be increased when it is combined with Naringenin.Experimental
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Aldosterone.Investigational
NefazodoneThe serum concentration of Aldosterone can be decreased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Aldosterone can be decreased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Nemonoxacin.Investigational
NeostigmineThe serum concentration of Aldosterone can be increased when it is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Aldosterone.Approved
NevirapineThe serum concentration of Aldosterone can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Aldosterone.Approved
NicorandilThe risk or severity of adverse effects can be increased when Aldosterone is combined with Nicorandil.Approved
NifedipineThe serum concentration of Aldosterone can be decreased when it is combined with Nifedipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Aldosterone.Approved
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Aldosterone.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Aldosterone.Approved, Withdrawn
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Aldosterone.Approved
NisoldipineThe serum concentration of Aldosterone can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Aldosterone can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Aldosterone can be increased when it is combined with Nitrendipine.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Aldosterone.Investigational
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Aldosterone.Approved
NorethisteroneThe serum concentration of Aldosterone can be decreased when it is combined with Norethisterone.Approved
NorfloxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Ofloxacin.Approved
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Aldosterone.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Aldosterone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Aldosterone.Approved
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Aldosterone.Approved
OmeprazoleThe serum concentration of Aldosterone can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Aldosterone.Vet Approved
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Aldosterone.Approved
OxandroloneAldosterone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Aldosterone.Approved
OxymetholoneAldosterone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Aldosterone.Withdrawn
P-NitrophenolThe serum concentration of Aldosterone can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Aldosterone.Approved, Vet Approved
Palmitic AcidThe serum concentration of Aldosterone can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Aldosterone.Approved, Investigational
PantoprazoleThe serum concentration of Aldosterone can be increased when it is combined with Pantoprazole.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Aldosterone.Approved
ParoxetineThe serum concentration of Aldosterone can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Aldosterone.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Aldosterone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerindoprilThe serum concentration of Aldosterone can be increased when it is combined with Perindopril.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Aldosterone.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Aldosterone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Aldosterone.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Aldosterone.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Aldosterone is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Aldosterone.Approved, Investigational
PimozideThe serum concentration of Aldosterone can be increased when it is combined with Pimozide.Approved
PiretanideAldosterone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Aldosterone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Aldosterone.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Aldosterone.Approved
Platelet Activating FactorThe serum concentration of Aldosterone can be decreased when it is combined with Platelet Activating Factor.Experimental
Polyestradiol phosphateThe serum concentration of Aldosterone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideAldosterone may increase the hypokalemic activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Aldosterone.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Aldosterone.Approved
PosaconazoleThe serum concentration of Aldosterone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Aldosterone.Approved
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Aldosterone.Approved
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Aldosterone.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Aldosterone.Approved, Vet Approved
PrimidoneThe serum concentration of Aldosterone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Aldosterone can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Aldosterone can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromestrieneThe serum concentration of Aldosterone can be increased when it is combined with Promestriene.Investigational
PromethazineThe serum concentration of Aldosterone can be increased when it is combined with Promethazine.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Aldosterone.Approved
PropafenoneThe serum concentration of Aldosterone can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Aldosterone.Approved, Investigational
ProtriptylineThe serum concentration of Aldosterone can be increased when it is combined with Protriptyline.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Aldosterone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Aldosterone is combined with Pyridostigmine.Approved
QuercetinThe serum concentration of Aldosterone can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Aldosterone.Approved
QuinacrineThe serum concentration of Aldosterone can be increased when it is combined with Quinacrine.Approved
QuinestrolThe serum concentration of Aldosterone can be increased when it is combined with Quinestrol.Approved
QuinethazoneAldosterone may increase the hypokalemic activities of Quinethazone.Approved
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Aldosterone.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Aldosterone.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Aldosterone is combined with Rabies vaccine.Approved
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Aldosterone.Approved
RanolazineThe serum concentration of Aldosterone can be increased when it is combined with Ranolazine.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Aldosterone.Withdrawn
ReboxetineThe serum concentration of Aldosterone can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Aldosterone can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Aldosterone can be decreased when it is combined with Reserpine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Aldosterone.Experimental, Investigational
RifabutinThe serum concentration of Aldosterone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Aldosterone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Aldosterone can be decreased when it is combined with Rifapentine.Approved
RilpivirineThe serum concentration of Aldosterone can be increased when it is combined with Rilpivirine.Approved
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Aldosterone.Approved, Investigational
RitonavirThe serum concentration of Aldosterone can be decreased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Aldosterone.Approved
RivastigmineThe risk or severity of adverse effects can be increased when Aldosterone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Aldosterone.Investigational, Withdrawn
RolapitantThe serum concentration of Aldosterone can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Aldosterone.Approved, Investigational
RosoxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Rosoxacin.Approved
S EquolThe serum concentration of Aldosterone can be increased when it is combined with S Equol.Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Aldosterone.Approved
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Aldosterone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Aldosterone.Approved
SaquinavirThe serum concentration of Aldosterone can be decreased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Aldosterone can be increased when it is combined with Scopolamine.Approved
SecoisolariciresinolThe serum concentration of Aldosterone can be increased when it is combined with Secoisolariciresinol.Investigational
SelegilineThe serum concentration of Aldosterone can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Aldosterone.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Aldosterone.Approved, Investigational
SertralineThe serum concentration of Aldosterone can be increased when it is combined with Sertraline.Approved
SilodosinThe serum concentration of Silodosin can be decreased when it is combined with Aldosterone.Approved
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Aldosterone.Approved
SimvastatinThe serum concentration of Aldosterone can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Aldosterone can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Aldosterone.Approved, Investigational
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Aldosterone.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Aldosterone.Approved
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Aldosterone.Approved, Investigational
SparfloxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Sparfloxacin.Approved
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Aldosterone.Experimental
SpironolactoneThe serum concentration of Aldosterone can be increased when it is combined with Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Aldosterone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Aldosterone.Investigational
St. John's WortThe serum concentration of Aldosterone can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololAldosterone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StaurosporineThe serum concentration of Aldosterone can be increased when it is combined with Staurosporine.Experimental
StreptozocinThe serum concentration of Aldosterone can be decreased when it is combined with Streptozocin.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Aldosterone.Approved
SulfinpyrazoneThe serum concentration of Aldosterone can be increased when it is combined with Sulfinpyrazone.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Aldosterone.Approved
SumatriptanThe serum concentration of Aldosterone can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Aldosterone can be increased when it is combined with Sunitinib.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Aldosterone.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Aldosterone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Aldosterone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe serum concentration of Aldosterone can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Aldosterone.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Aldosterone.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Aldosterone.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Aldosterone.Approved
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Aldosterone.Approved
TelithromycinThe serum concentration of Aldosterone can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Aldosterone can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Temafloxacin.Withdrawn
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Aldosterone.Approved
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Aldosterone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Aldosterone.Vet Approved
TerazosinThe serum concentration of Aldosterone can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Aldosterone can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Aldosterone.Approved
TesmilifeneThe serum concentration of Aldosterone can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Aldosterone can be increased when it is combined with Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Aldosterone is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Aldosterone.Approved
TiboloneThe serum concentration of Aldosterone can be increased when it is combined with Tibolone.Approved
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Aldosterone.Approved
TimololThe serum concentration of Timolol can be decreased when it is combined with Aldosterone.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Aldosterone.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Aldosterone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Aldosterone.Approved
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Aldosterone.Approved
TopotecanThe serum concentration of Topotecan can be decreased when it is combined with Aldosterone.Approved, Investigational
TorasemideAldosterone may increase the hypokalemic activities of Torasemide.Approved
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Aldosterone.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Aldosterone.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Aldosterone.Approved
TrazodoneThe serum concentration of Aldosterone can be decreased when it is combined with Trazodone.Approved, Investigational
TrichlorfonThe risk or severity of adverse effects can be increased when Aldosterone is combined with Trichlorfon.Vet Approved
TrichlormethiazideAldosterone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe serum concentration of Aldosterone can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Aldosterone can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Aldosterone can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Aldosterone can be increased when it is combined with Trimipramine.Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Aldosterone.Approved
TroleandomycinThe serum concentration of Aldosterone can be increased when it is combined with Troleandomycin.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Aldosterone is combined with Tubocurarine.Approved
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Aldosterone.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Aldosterone.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Aldosterone.Investigational, Withdrawn
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Aldosterone.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Aldosterone.Approved
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Aldosterone.Approved
VerapamilThe serum concentration of Aldosterone can be decreased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Aldosterone.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Aldosterone.Approved, Investigational
VinorelbineThe serum concentration of Aldosterone can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Aldosterone.Approved
VoriconazoleThe serum concentration of Aldosterone can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinAldosterone may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Aldosterone.Approved
ZeranolThe serum concentration of Aldosterone can be increased when it is combined with Zeranol.Vet Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Aldosterone.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Aldosterone.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Aldosterone can be increased when it is combined with Zimelidine.Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Aldosterone.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Jack Fishman, Elliot Hahn, Gregory A. Smith, “Aldosterone biosynthesis inhibitor.” U.S. Patent US5120724, issued December, 1969.

US5120724
General References
  1. Williams JS, Williams GH: 50th anniversary of aldosterone. J Clin Endocrinol Metab. 2003 Jun;88(6):2364-72. [PubMed:12788829 ]
External Links
ATC CodesH02AA01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (68.4 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9943
Blood Brain Barrier+0.921
Caco-2 permeable+0.8527
P-glycoprotein substrateSubstrate0.7719
P-glycoprotein inhibitor INon-inhibitor0.738
P-glycoprotein inhibitor IINon-inhibitor0.7441
Renal organic cation transporterNon-inhibitor0.6832
CYP450 2C9 substrateNon-substrate0.8059
CYP450 2D6 substrateNon-substrate0.904
CYP450 3A4 substrateSubstrate0.7278
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9189
CYP450 2D6 inhibitorNon-inhibitor0.9251
CYP450 2C19 inhibitorNon-inhibitor0.9434
CYP450 3A4 inhibitorNon-inhibitor0.8795
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8737
Ames testNon AMES toxic0.9073
CarcinogenicityNon-carcinogens0.9543
BiodegradationNot ready biodegradable0.9279
Rat acute toxicity1.5456 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9242
hERG inhibition (predictor II)Non-inhibitor0.5136
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point166.5 °CPhysProp
water solubility51.2 mg/L (at 37 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.08HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.148 mg/mLALOGPS
logP1.54ALOGPS
logP1.06ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)13.82ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area91.67 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity96.79 m3·mol-1ChemAxon
Polarizability38.87 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (12.2 KB)
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative Parents
Substituents
  • 21-hydroxysteroid
  • Progestogin-skeleton
  • Pregnane-skeleton
  • 20-oxosteroid
  • 18-oxosteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • 3-oxosteroid
  • 3-oxo-delta-4-steroid
  • Delta-4-steroid
  • Cyclic alcohol
  • Alpha-hydroxy ketone
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Carbonyl group
  • Aldehyde
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Zinc ion binding
Specific Function:
Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates target genes. The effect of MC is to increase ion and water transport and thus raise extracellular fluid volume and blood pressure and lower potassium levels.
Gene Name:
NR3C2
Uniprot ID:
P08235
Molecular Weight:
107066.575 Da
References
  1. Bruner KL, Derfoul A, Robertson NM, Guerriero G, Fernandes-Alnemri T, Alnemri ES, Litwack G: The unliganded mineralocorticoid receptor is associated with heat shock proteins 70 and 90 and the immunophilin FKBP-52. Recept Signal Transduct. 1997;7(2):85-98. [PubMed:9392437 ]
  2. Bunda S, Liu P, Wang Y, Liu K, Hinek A: Aldosterone induces elastin production in cardiac fibroblasts through activation of insulin-like growth factor-I receptors in a mineralocorticoid receptor-independent manner. Am J Pathol. 2007 Sep;171(3):809-19. [PubMed:17724138 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid 11-beta-monooxygenase activity
Specific Function:
Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochrome P450 XIB.
Gene Name:
CYP11B1
Uniprot ID:
P15538
Molecular Weight:
57572.44 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid 11-beta-monooxygenase activity
Specific Function:
Preferentially catalyzes the conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone.
Gene Name:
CYP11B2
Uniprot ID:
P19099
Molecular Weight:
57559.62 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid 17-alpha-monooxygenase activity
Specific Function:
Conversion of pregnenolone and progesterone to their 17-alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both the 17-alpha-hydroxylation and the 17,20-lyase reaction. Involved in sexual development during fetal life and at puberty.
Gene Name:
CYP17A1
Uniprot ID:
P05093
Molecular Weight:
57369.995 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91. [PubMed:12387747 ]
  2. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R: Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem. 1992 Dec 5;267(34):24248-52. [PubMed:1360010 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Also relative uptake activity ratio of carnitine to TEA is 11.3.
Gene Name:
SLC22A5
Uniprot ID:
O76082
Molecular Weight:
62751.08 Da
References
  1. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PubMed:10525100 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Kanai N, Lu R, Bao Y, Wolkoff AW, Schuster VL: Transient expression of oatp organic anion transporter in mammalian cells: identification of candidate substrates. Am J Physiol. 1996 Feb;270(2 Pt 2):F319-25. [PubMed:8779893 ]
  2. Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. [PubMed:8786566 ]
Comments
comments powered by Disqus
Drug created on September 11, 2007 11:49 / Updated on August 17, 2016 12:24